Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1
- PMID: 38539569
- PMCID: PMC10968822
- DOI: 10.3390/cancers16061237
Regulation of PD-L1 Expression by YY1 in Cancer: Therapeutic Efficacy of Targeting YY1
Abstract
During the last decade, we have witnessed several milestones in the treatment of various resistant cancers including immunotherapeutic strategies that have proven to be superior to conventional treatment options, such as chemotherapy and radiation. This approach utilizes the host's immune response, which is triggered by cancer cells expressing tumor-associated antigens or neoantigens. The responsive immune cytotoxic CD8+ T cells specifically target and kill tumor cells, leading to tumor regression and prolongation of survival in some cancers; however, some cancers may exhibit resistance due to the inactivation of anti-tumor CD8+ T cells. One mechanism by which the anti-tumor CD8+ T cells become dysfunctional is through the activation of the inhibitory receptor programmed death-1 (PD-1) by the corresponding tumor cells (or other cells in the tumor microenvironment (TME)) that express the programmed death ligand-1 (PD-L1). Hence, blocking the PD-1/PD-L1 interaction via specific monoclonal antibodies (mAbs) restores the CD8+ T cells' functions, leading to tumor regression. Accordingly, the Food and Drug Administration (FDA) has approved several checkpoint antibodies which act as immune checkpoint inhibitors. Their clinical use in various resistant cancers, such as metastatic melanoma and non-small-cell lung cancer (NSCLC), has shown significant clinical responses. We have investigated an alternative approach to prevent the expression of PD-L1 on tumor cells, through targeting the oncogenic transcription factor Yin Yang 1 (YY1), a known factor overexpressed in many cancers. We report the regulation of PD-L1 by YY1 at the transcriptional, post-transcriptional, and post-translational levels, resulting in the restoration of CD8+ T cells' anti-tumor functions. We have performed bioinformatic analyses to further explore the relationship between both YY1 and PD-L1 in cancer and to corroborate these findings. In addition to its regulation of PD-L1, YY1 has several other anti-cancer activities, such as the regulation of proliferation and cell viability, invasion, epithelial-mesenchymal transition (EMT), metastasis, and chemo-immuno-resistance. Thus, targeting YY1 will have a multitude of anti-tumor activities resulting in a significant obliteration of cancer oncogenic activities. Various strategies are proposed to selectively target YY1 in human cancers and present a promising novel therapeutic approach for treating unresponsive cancer phenotypes. These findings underscore the distinct regulatory roles of YY1 and PD-L1 (CD274) in cancer progression and therapeutic response.
Keywords: PD-L1; T cells; YY1; cancer; immunotherapy; inhibitors; overexpression; resistance.
Conflict of interest statement
The authors declare no conflicts of interests.
Figures
![Figure 2](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10968822/bin/cancers-16-01237-g002.gif)
![Figure 3](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10968822/bin/cancers-16-01237-g003.gif)
![Figure 4](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10968822/bin/cancers-16-01237-g004.gif)
![Figure 5](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10968822/bin/cancers-16-01237-g005.gif)
![Figure 6](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10968822/bin/cancers-16-01237-g006.gif)
![Figure 8](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10968822/bin/cancers-16-01237-g008.gif)
![Figure 1](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10968822/bin/cancers-16-01237-g001.gif)
![Figure 7](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10968822/bin/cancers-16-01237-g007.gif)
![Figure 9](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/10968822/bin/cancers-16-01237-g009.gif)
Similar articles
-
YY1 regulates cancer cell immune resistance by modulating PD-L1 expression.Drug Resist Updat. 2019 Mar;43:10-28. doi: 10.1016/j.drup.2019.04.001. Epub 2019 Apr 9. Drug Resist Updat. 2019. PMID: 31005030 Review.
-
Cross-Talks between Raf Kinase Inhibitor Protein and Programmed Cell Death Ligand 1 Expressions in Cancer: Role in Immune Evasion and Therapeutic Implications.Cells. 2024 May 17;13(10):864. doi: 10.3390/cells13100864. Cells. 2024. PMID: 38786085 Free PMC article. Review.
-
Nitric Oxide-Mediated Enhancement and Reversal of Resistance of Anticancer Therapies.Antioxidants (Basel). 2019 Sep 17;8(9):407. doi: 10.3390/antiox8090407. Antioxidants (Basel). 2019. PMID: 31533363 Free PMC article. Review.
-
Isorhamnetin and anti-PD-L1 antibody dual-functional mesoporous silica nanoparticles improve tumor immune microenvironment and inhibit YY1-mediated tumor progression.J Nanobiotechnology. 2023 Jul 5;21(1):208. doi: 10.1186/s12951-023-01967-3. J Nanobiotechnology. 2023. PMID: 37408047 Free PMC article.
-
ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.Theranostics. 2021 Jan 19;11(7):3392-3416. doi: 10.7150/thno.52435. eCollection 2021. Theranostics. 2021. PMID: 33537094 Free PMC article.
Cited by
-
LncRNA PTENP1/miR-21/PTEN Axis Modulates EMT and Drug Resistance in Cancer: Dynamic Boolean Modeling for Cell Fates in DNA Damage Response.Int J Mol Sci. 2024 Jul 29;25(15):8264. doi: 10.3390/ijms25158264. Int J Mol Sci. 2024. PMID: 39125832 Free PMC article.
References
Publication types
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials